China Oncology ›› 2022, Vol. 32 ›› Issue (7): 606-613.doi: 10.19401/j.cnki.1007-3639.2022.07.004

• Article • Previous Articles     Next Articles

Establishment of a mouse myocarditis model induced by programmed death-1 inhibitor

CHEN Yifan1,2,3()(), CHENG Leilei2,3,4()(), SHEN Yihui2,3,4, ZHANG Hui2,3,4, WANG Xuejun2,3,4, XU Yuchen1,2,3, GE Junbo1,2,3   

  1. 1. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
    2. Shanghai Institute of Cardiovascular Diseases, Shanghai 200032, China
    3. National Clinical Research Center for Interventional Medicine, Shanghai 200032, China
    4. Department of Echocardiography, Zhongshan Hospital, Fudan University, Shanghai 200032, China
  • Received:2022-03-08 Online:2022-07-30 Published:2022-08-09
  • Contact: CHENG Leilei E-mail:21111210020@m.fudan.edu.cn;cheng.leilei@zs-hospital.sh.cn

Abstract:

Background and purpose: Myocarditis induced by programmed death-1 (PD-1) inhibitors is in urgent need of animal models to explore therapeutic targets. The study aimed to figure out the best modeling method of this typical autoimmune myocarditis in mice. Methods: Thirty 6-week-old healthy male BALB/c mice were numbered and randomly divided into control group, autoimmune myocarditis group (TnⅠgroup) and immune checkpoint inhibitor (ICI)-related myocarditis group (TnⅠ+anti-PD-1 group), 10 in each group. Except for the control group, mice were subcutaneously injected with 0.1 mL complete Freund’s adjuvant containing 0.25 mg of mouse cardiac TnⅠ peptide on day 1 and day 7, respectively. From day 7, TnⅠ+anti-PD-1 group received intraperitoneal injection of PD-1 inhibitor at 5 mg/kg each time, once every 2 d, for a total of 5 times with a cumulative dose of 25 mg/kg. The general state, mortality, cardiac index, echocardiography, myocardial pathology and the levels of creatine kinase (CK) and CK isoenzyme (CK-MB) in serum were observed. Results: Compared with control group, the mass of mice in both TnⅠ and TnⅠ+anti-PD-1 groups decreased significantly on day 21 and day 56 (P<0.05, P<0.01), and there was a significant difference between these 2 groups (P<0.05). Both had significantly decreased food intake (compared with control group, P<0.05, P<0.01). The mortality rates were 0% and 10% on day 21, and 10% and 20% on day 56 in TnⅠ and TnⅠ+anti-PD-1 groups, respectively. On day 56, no significant increase in cardiac index could be observed in TnⅠ group (P>0.05), while a significant rise of cardiac index (P<0.05) with a decrease in left ventricular ejection fraction (EF) (P<0.001) were detected in TnⅠ+anti-PD-1 group. During the acute myocarditis stage, mild subepicardial inflammatory infiltration was found in TnⅠ group; Severe subepicardial inflammatory infiltration and myocardial cell necrosis were seen in TnⅠ+anti-PD-1 group. During the dilated cardiomyopathy stage, the infiltrated inflammatory cells in TnⅠ group decreased, mild boundaries unclear and cytoplasm vacuolization could be observed; TnⅠ+anti-PD-1 group also had decreased inflammatory infiltration while underwent more severe cell necrosis and vacuolization with nuclear atypia. On day 56, serum CK and CK-MB in TnⅠ+anti-PD-1 group rose significantly (P<0.001), which was more obvious compared with TnⅠ group (CK: P<0.01; CK-MB: P<0.05). Conclusion: A PD-1 inhibitor-induced myocarditis model with low mortality was established in mice, characterized by acute and chronic autoimmune myocardial inflammation, decreased ejection fraction and increased myocardial enzyme spectrum. A mouse cardiac TnⅠ peptide fragment was particularly designed and synthesized for modeling.

Key words: Programmed death-1 inhibitor, Immune checkpoint inhibitor-associated myocarditis, Mouse, Model

CLC Number: